167 related articles for article (PubMed ID: 10693916)
1. Free radical scavenging activity of sulfonylureas: a clinical assessment of the effect of gliclazide.
Jennings PE; Belch JJ
Metabolism; 2000 Feb; 49(2 Suppl 1):23-6. PubMed ID: 10693916
[TBL] [Abstract][Full Text] [Related]
2. [Free radical scavenging activity of sulfonylureas: a clinical assessment of the effectiveness of gliclazide].
Jennings PE; Belch JJ
Ter Arkh; 2001; 73(4):27-31. PubMed ID: 11494442
[TBL] [Abstract][Full Text] [Related]
3. Effects of gliclazide on platelet reactivity and free radicals in type II diabetic patients: clinical assessment.
Jennings PE; Scott NA; Saniabadi AR; Belch JJ
Metabolism; 1992 May; 41(5 Suppl 1):36-9. PubMed ID: 1574014
[TBL] [Abstract][Full Text] [Related]
4. Diabetic endothelial dysfunction: effect of free radical scavenging in Type 2 diabetic patients.
De Mattia G; Laurenti O; Fava D
J Diabetes Complications; 2003; 17(2 Suppl):30-5. PubMed ID: 12623166
[TBL] [Abstract][Full Text] [Related]
5. Glibenclamide vs gliclazide in reducing oxidative stress in patients of noninsulin dependent diabetes mellitus--a double blind randomized study.
Chugh SN; Dhawan R; Kishore K; Sharma A; Chugh K
J Assoc Physicians India; 2001 Aug; 49():803-7. PubMed ID: 11837468
[TBL] [Abstract][Full Text] [Related]
6. Vascular benefits of gliclazide beyond glycemic control.
Jennings PE
Metabolism; 2000 Oct; 49(10 Suppl 2):17-20. PubMed ID: 11078471
[TBL] [Abstract][Full Text] [Related]
7. Characteristics of pancreatic beta-cell secretion in Type 2 diabetic patients treated with gliclazide and glibenclamide.
van der Wal PS; Heine RJ
Diabetes Res Clin Pract; 2001 May; 52(2):103-11. PubMed ID: 11311964
[TBL] [Abstract][Full Text] [Related]
8. Comparison of gliclazide and glibenclamide treatment in non-insulin-dependent diabetes.
Baba S; Nakagawa S; Takebe K; Goto Y; Maezawa H; Takeda R; Sakamoto N; Fukui I
Tohoku J Exp Med; 1983 Dec; 141 Suppl():693-706. PubMed ID: 6440313
[TBL] [Abstract][Full Text] [Related]
9. Long-term effects on lipids and lipoproteins of pioglitazone versus gliclazide addition to metformin and pioglitazone versus metformin addition to sulphonylurea in the treatment of type 2 diabetes.
Betteridge DJ; Vergès B
Diabetologia; 2005 Dec; 48(12):2477-81. PubMed ID: 16283239
[TBL] [Abstract][Full Text] [Related]
10. Lack of effect of gliclazide on platelet aggregation in insulin-treated and non-insulin-treated diabetes: a two-year controlled study.
Larkins RG; Jerums G; Taft JL; Godfrey H; Smith IL; Martin TJ
Diabetes Res Clin Pract; 1988 Jan; 4(2):81-7. PubMed ID: 3125029
[TBL] [Abstract][Full Text] [Related]
11. Mortality outcomes of different sulphonylurea drugs: the results of a 14-year cohort study of type 2 diabetic patients.
Bo S; Castiglione A; Ghigo E; Gentile L; Durazzo M; Cavallo-Perin P; Ciccone G
Eur J Endocrinol; 2013 Jul; 169(1):117-26. PubMed ID: 23660643
[TBL] [Abstract][Full Text] [Related]
12. Gliclazide improves anti-oxidant status and nitric oxide-mediated vasodilation in Type 2 diabetes.
Fava D; Cassone-Faldetta M; Laurenti O; De Luca O; Ghiselli A; De Mattia G
Diabet Med; 2002 Sep; 19(9):752-7. PubMed ID: 12207812
[TBL] [Abstract][Full Text] [Related]
13. Systematic review and meta-analysis of the efficacy and hypoglycemic safety of gliclazide versus other insulinotropic agents.
Chan SP; Colagiuri S
Diabetes Res Clin Pract; 2015 Oct; 110(1):75-81. PubMed ID: 26361859
[TBL] [Abstract][Full Text] [Related]
14. [Clinical evaluation of gliquidone--short acting sulfonylurea derivative--comparison with glibenclamide and gliclazide].
Rupprecht E; König E; Limmer J
Pol Tyg Lek; 1993 Apr; 48 Suppl 1():31-2. PubMed ID: 8516203
[No Abstract] [Full Text] [Related]
15. In vitro and in vivo antioxidant properties of gliclazide.
O'Brien RC; Luo M; Balazs N; Mercuri J
J Diabetes Complications; 2000; 14(4):201-6. PubMed ID: 11004429
[TBL] [Abstract][Full Text] [Related]
16. Association of gliclazide and left ventricular mass in type 2 diabetic patients.
Pan NH; Lee TM; Lin MS; Huang CL; Chang NC
Diabetes Res Clin Pract; 2006 Nov; 74(2):121-8. PubMed ID: 16631274
[TBL] [Abstract][Full Text] [Related]
17. Preventive and therapeutic effects of gliclazide on diabetic retinopathy: comparison with glibenclamide treatment.
Minami N; Ikeda Y; Abe M
Tohoku J Exp Med; 1983 Dec; 141 Suppl():707-11. PubMed ID: 6440314
[TBL] [Abstract][Full Text] [Related]
18. Effects of gliclazide on platelet aggregation and the plasminogen activator inhibitor type 1 level in patients with type 2 diabetes mellitus.
Konya H; Hasegawa Y; Hamaguchi T; Satani K; Umehara A; Katsuno T; Ishikawa T; Miuchi M; Kohri K; Suehiro A; Kakishita E; Miyagawa J; Namba M
Metabolism; 2010 Sep; 59(9):1294-9. PubMed ID: 20070990
[TBL] [Abstract][Full Text] [Related]
19. Metformin or gliclazide, rather than glibenclamide, attenuate progression of carotid intima-media thickness in subjects with type 2 diabetes.
Katakami N; Yamasaki Y; Hayaishi-Okano R; Ohtoshi K; Kaneto H; Matsuhisa M; Kosugi K; Hori M
Diabetologia; 2004 Nov; 47(11):1906-13. PubMed ID: 15565373
[TBL] [Abstract][Full Text] [Related]
20. Comparison of diabetic control in type 2 (non-insulin dependent) diabetic patients treated with different sulphonylureas.
Harrower AD
Curr Med Res Opin; 1985; 9(10):676-80. PubMed ID: 3935376
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
